Intraperitoneal Daptomycin used to Successfully Treat Vancomycin-Resistant Enterococcus Peritonitis

Hassoun, Ali; Coomer, Roger W.; Mendez-Vigo, Luke

doi:10.1177/089686080902900614

Cited by 19 publications

(13 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 94 Daptomycin is a treatment option for IAIs and has been administered intraperitoneally for successful treatment of VRE peritonitis. 95 It achieves high renal clearance at 50%–70%, giving it a favorable profile for the treatment of VRE UTIs. 96 Daptomycin is a preferred agent for the treatment of bacteremia, IE, UTI, CNS infection, IAI, and SSSI, but higher doses should be considered for the treatment of serious VRE infections, and synergy with a β-lactam can be attempted for refractory cases.…”

Section: Optimal Managementmentioning

confidence: 99%

Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management

O’Driscoll¹,

Crank²

2015

IDR

294

202

View full text Add to dashboard Cite

Since its discovery in England and France in 1986, vancomycin-resistant Enterococcus has increasingly become a major nosocomial pathogen worldwide. Enterococci are prolific colonizers, with tremendous genome plasticity and a propensity for persistence in hospital environments, allowing for increased transmission and the dissemination of resistance elements. Infections typically present in immunosuppressed patients who have received multiple courses of antibiotics in the past. Virulence is variable, and typical clinical manifestations include bacteremia, endocarditis, intra-abdominal and pelvic infections, urinary tract infections, skin and skin structure infections, and, rarely, central nervous system infections. As enterococci are common colonizers, careful consideration is needed before initiating targeted therapy, and source control is first priority. Current treatment options including linezolid, daptomycin, quinupristin/dalfopristin, and tigecycline have shown favorable activity against various vancomycin-resistant Enterococcus infections, but there is a lack of randomized controlled trials assessing their efficacy. Clearer distinctions in preferred therapies can be made based on adverse effects, drug interactions, and pharmacokinetic profiles. Although combination therapies and newer agents such as tedizolid, telavancin, dalbavancin, and oritavancin hold promise for the future treatment of vancomycin-resistant Enterococcus infections, further studies are needed to assess their possible clinical impact, especially in the treatment of serious infections.

show abstract

Section: Optimal Managementmentioning

confidence: 99%

Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management

O’Driscoll¹,

Crank²

2015

IDR

294

202

View full text Add to dashboard Cite

show abstract

“…A separate case report also showed that intraperitoneal daptomycin (15 mg/kg once weekly) was successful in the treatment of continuous ambulatory peritoneal dialysis-related peritonitis due to vancomycin-resistant E. faecium . 89 …”

Section: Clinical Experience With Daptomycin In Enterococcal Infectiomentioning

confidence: 99%

A potential role for daptomycin in enterococcal infections: what is the evidence?

Cantón

Ruíz-Garbajosa

Chaves

et al. 2010

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

Nosocomial infections caused by enterococci present a challenge for clinicians because treatment options are often limited due to the widespread occurrence of strains resistant to multiple antibiotics, including vancomycin. Daptomycin is a first-in-class cyclic lipopeptide that has proven efficacy for the treatment of Gram-positive infections. Although methicillin-resistant Staphylococcus aureus has been the most prominent target in the clinical development of daptomycin, this agent has demonstrated potent bactericidal activity in enterococcal infection models and has been used for the treatment of enterococcal infections in humans. In recent years, large-scale susceptibility studies have shown that daptomycin is active against >98% of enterococci tested, irrespective of their susceptibility to other antibacterial agents. This lack of cross-resistance reflects the fact that daptomycin has a mode of action distinct from those of other antibiotics, including glycopeptides. While there are limited data available from randomized controlled trials, extensive clinical experience with daptomycin in enterococcal infections (including bacteraemia, endocarditis, skin and soft tissue infections, bone and joint infections and urinary tract infections) has been reported. This growing body of evidence provides useful insights regarding the efficacy of daptomycin against enterococci in clinical settings.

show abstract

“…Daptomycin could also be an option, but it must be administered intraperitoneally because of its poor penetration to the peritoneal cavity when given intravenously. Its potential instability in glucose-based solutions is another issue (27,28). Other newer alternatives, including tigecycline or oritavancin, have not been tested in enterococcal PD-related peritonitis.…”

mentioning

confidence: 99%

Enterococcal Peritonitis in Peritoneal Dialysis Patients: Last Name Matters

2011

View full text Add to dashboard Cite

Intraperitoneal Daptomycin used to Successfully Treat Vancomycin-Resistant Enterococcus Peritonitis

Cited by 19 publications

References 20 publications

Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management

Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management

A potential role for daptomycin in enterococcal infections: what is the evidence?

Enterococcal Peritonitis in Peritoneal Dialysis Patients: Last Name Matters

Contact Info

Product

Resources

About